Medical Condition News

RSS

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

Ketogenic diet may benefit patients with myoclonic-astatic epilepsy

Many children with certain forms of epilepsy achieve seizure control through a stringent medically supervised diet, either the ketogenic diet (KD) or a Modified Atkins Diet (MAD). When to use these diets and the mechanisms underlying their anticonvulsant effect are not well defined. Research presented here at the 64th American Epilepsy Society annual meeting provides new insight into when and how these diets work.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.

6 Dec 2010

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

New drug for non-Hodgkin’s lymphoma shows promise

Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin’s lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.

5 Dec 2010

Multiple sclerosis therapy breakthrough with stem cells

There seems to a glimmer of hope for tens of thousands of multiple sclerosis sufferers as researchers discover a way to repair damaged nerves with stem cells. The British team says their findings could lead to the development of drugs that repair nerves in the brain and spinal cord and potentially reverse some of the symptoms of MS.

5 Dec 2010

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

Hospital for Special Surgery announced the creation of the Center for Musculoskeletal Outcomes and Patient Oriented Research to translate information collected from an extensive patient population into studies that will guide experts in preventing, diagnosing and treating musculoskeletal disorders.

4 Dec 2010

NCI director ignorant of cancer prevention, says coalition

On October 22, 2010, Senator Chuck Grassley, ranking member of the Senate Finance Committee, wrote to Dr. Harold Varmus, who was appointed director of the National Cancer Institute (NCI) by President Obama three months previously. The Senator raised questions on the amount of "sponsored travel," sometimes a dozen or more trips a year and almost exclusively to international conferences paid for by outside organizations or companies, taken in recent years by "numerous NCI employees, notably senior leadership."

4 Dec 2010

AANS injury prevention tips during winter holiday season

During the winter holiday season there are many warnings in the news about preventing house fires caused by Christmas trees and faulty electrical wiring. There are also warnings about too much merriment leading to alcohol-related motor vehicle accidents. A lesser known fact is the risk of head injury related to hanging and taking down Christmas decorations.

4 Dec 2010

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.

4 Dec 2010

Access adds patient experience testimonial video to MuGard website

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.

4 Dec 2010

Robotics and machine-brain interface may benefit paraplegics

A ballet dancer grasps her partner's hand to connect for a pas de deux. Later that night, in the dark, she reaches for her calf to massage a sore spot. Her brain is using different "maps" to plan for each of these movements, according to a new study at UC Santa Barbara.

4 Dec 2010

Study reveals higher mortality rate among veteran status epilepticus patients

Status epilepticus (SE) is a true medical and neurologic emergency. To better understand the causes, treatment approaches and associated outcomes among SE patients, investigators at the Veterans Affairs Greater Los Angeles Healthcare System retrospectively reviewed all SE cases treated within their system over an eight year period.

4 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

ETP, EF announce latest grant recipients of New Therapy Grants Program

The Epilepsy Therapy Project and the Epilepsy Foundation today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of two non-profit epilepsy organizations, to advance promising epilepsy research in clinical development.

4 Dec 2010

Medical Condition News

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Ketogenic diet may benefit patients with myoclonic-astatic epilepsy

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

New drug for non-Hodgkin’s lymphoma shows promise

Multiple sclerosis therapy breakthrough with stem cells

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

NCI director ignorant of cancer prevention, says coalition

AANS injury prevention tips during winter holiday season

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Access adds patient experience testimonial video to MuGard website

Robotics and machine-brain interface may benefit paraplegics

Study reveals higher mortality rate among veteran status epilepticus patients

Closer to restoring vision loss due to optic nerve damage

ETP, EF announce latest grant recipients of New Therapy Grants Program

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Latest News